JPWO2020251924A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020251924A5
JPWO2020251924A5 JP2021573449A JP2021573449A JPWO2020251924A5 JP WO2020251924 A5 JPWO2020251924 A5 JP WO2020251924A5 JP 2021573449 A JP2021573449 A JP 2021573449A JP 2021573449 A JP2021573449 A JP 2021573449A JP WO2020251924 A5 JPWO2020251924 A5 JP WO2020251924A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537142A5 (https=
JP7807238B2 (ja
JP2022537142A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036771 external-priority patent/WO2020251924A1/en
Publication of JP2022537142A publication Critical patent/JP2022537142A/ja
Publication of JP2022537142A5 publication Critical patent/JP2022537142A5/ja
Publication of JPWO2020251924A5 publication Critical patent/JPWO2020251924A5/ja
Priority to JP2025112473A priority Critical patent/JP2025138816A/ja
Application granted granted Critical
Publication of JP7807238B2 publication Critical patent/JP7807238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573449A 2019-06-12 2020-06-09 骨形成タンパク質6に対するヒト抗体 Active JP7807238B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112473A JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860597P 2019-06-12 2019-06-12
US62/860,597 2019-06-12
PCT/US2020/036771 WO2020251924A1 (en) 2019-06-12 2020-06-09 Human antibodies to bone morphogenetic protein 6

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112473A Division JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Publications (4)

Publication Number Publication Date
JP2022537142A JP2022537142A (ja) 2022-08-24
JP2022537142A5 JP2022537142A5 (https=) 2023-06-15
JPWO2020251924A5 true JPWO2020251924A5 (https=) 2023-06-15
JP7807238B2 JP7807238B2 (ja) 2026-01-27

Family

ID=71944214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573449A Active JP7807238B2 (ja) 2019-06-12 2020-06-09 骨形成タンパク質6に対するヒト抗体
JP2025112473A Pending JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112473A Pending JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Country Status (6)

Country Link
EP (1) EP3983436A1 (https=)
JP (2) JP7807238B2 (https=)
AU (1) AU2020292246A1 (https=)
CA (1) CA3141266A1 (https=)
MA (1) MA56203A (https=)
WO (1) WO2020251924A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US20140086919A1 (en) 2012-09-24 2014-03-27 Herbert Y. Lin Methods and compositons for regulating iron homeostasis by modulation of bmp-6
AU2016211890B2 (en) * 2008-11-13 2018-03-22 The General Hospital Corporation Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) * 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists

Similar Documents

Publication Publication Date Title
JP2025111463A5 (https=)
JP5307030B2 (ja) PEG化AβFAB
KR102366682B1 (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
IL269003B1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
CN112969719A (zh) 双功能融合蛋白及其医药用途
CA2189015A1 (en) Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
CA2400559A1 (en) Humanized antibodies that sequester .alpha..beta. peptide
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2024024114A5 (https=)
JP2015503909A5 (https=)
CN107921129B (zh) 组合及其用途
JP2020522280A5 (https=)
JP2020522281A5 (https=)
KR20200104314A (ko) Lag-3 항체 약학 조성물 및 이의 용도
JP2019505166A5 (https=)
JP2021510523A5 (https=)
JP2021533806A5 (https=)
JPWO2020227457A5 (https=)
JPWO2020251924A5 (https=)
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JPWO2020257289A5 (https=)
JPWO2019140216A5 (https=)
JPWO2022159875A5 (https=)